Document Detail

Mechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanoma.
MedLine Citation:
PMID:  23037806     Owner:  NLM     Status:  Publisher    
Allovectin (velimogene aliplasmid) is a cancer immunotherapeutic currently completing a pivotal phase 3 study for metastatic melanoma. Consisting of a bicistronic plasmid encoding both major histocompatibility complex (MHC) class I heavy and light chains (HLA-B7 and β2-microglobulin, respectively) formulated with a cationic lipid-based system, it is designed for direct intratumoral administration. Following injection into a single lesion, the product is intended to induce anti-tumor immune responses against both treated and distal lesions. Both the plasmid and lipid components of Allovectin contribute to the biological activity of the drug product, and its therapeutic activity is hypothesized to derive from multiple mechanisms of actions (MOAs). These include the induction of both cytotoxic T-cell and innate immune responses directed against allogeneic as well as tumor-derived targets, consequences of both an increased MHC class I expression on tumor cells and the induction of a localized immune/inflammatory response. In this paper, we review Allovectin's proposed MOAs, placing their contributions in the context of anti-tumor immunity and highlighting both preclinical and clinical supporting data.Cancer Gene Therapy advance online publication, 5 October 2012; doi:10.1038/cgt.2012.69.
J Doukas; A Rolland
Related Documents :
9496836 - Adrenocortical tumor in a patient with familial adenomatous polyposis: a case associate...
12621116 - Differential effect of dca treatment on the pyruvate dehydrogenase complex in patients ...
9236836 - P53 and k-ras mutational genotyping in pulmonary carcinosarcoma, spindle cell carcinoma...
16575206 - Elegance, silence and nonsense in the mutations literature for solid tumors.
1855216 - Therapy of human cervical carcinoma with monoclonal antibody-pseudomonas exotoxin conju...
23481326 - Targeting mir-21 for the therapy of pancreatic cancer.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-05
Journal Detail:
Title:  Cancer gene therapy     Volume:  -     ISSN:  1476-5500     ISO Abbreviation:  Cancer Gene Ther.     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-5     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9432230     Medline TA:  Cancer Gene Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Vical Incorporated, San Diego, CA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Case Report: Free Combined Osteo-Tendo-Cutaneous Flap from the Medial Femoral Condyle for Coverage o...
Next Document:  Tissue inhibitor of metalloproteinases-3 transfer suppresses malignant behaviors of colorectal cance...